Delayed-release formulation for reducing the frequency of urination and method of use thereof

Abstract

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.

1 . A method for reducing the frequency of urination, comprising:
 administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a first analgesic agent,   wherein said pharmaceutical composition is formulated in delayed-release formulation and wherein said first analgesic agent is administered orally at a daily dose of 5 mg to 2000 mg.   
     
     
         2 . The method of  claim 1 , wherein said delayed-release formulation comprises a material selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, methyl hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycols, polyvinylpyrrolidone, methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, and ethylcellulose. 
     
     
         3 . The method of  claim 2 , wherein said delayed-release formulation further comprises glyceryl monostearate or glyceryl distearate. 
     
     
         4 . The method of  claim 1 , wherein said delayed-release formulation comprises a water insoluble capsule body closed at one end with an insoluble, but permeable and swellable hydrogel plug, wherein said plug comprises a material selected from the group consisting of polymethacrylates, erodible compressed polymers, congealed melted polymer and enzymatically controlled erodible polymers. 
     
     
         5 . The method of  claim 1 , wherein said delayed-release formulation comprises an enteric coating. 
     
     
         6 . The method of  claim 1 , wherein said first analgesic agent is selected from the group consisting of aspirin, ibuprofen, naproxen, and acetaminophen, and wherein said first analgesic agent is administered orally at a daily dose of 50 mg to 500 mg. 
     
     
         7 . The method of  claim 6 , wherein said first analgesic agent is administered orally at a daily dose of 100 mg to 500 mg. 
     
     
         8 . The method of  claim 7 , wherein said first analgesic agent is administered orally at a daily dose of 250 mg to 500 mg. 
     
     
         9 . The method of  claim 1 , wherein said first analgesic agent is administered orally at a daily dose of 250 mg to 1000 mg. 
     
     
         10 . The method of  claim 1 , wherein said pharmaceutical composition further comprises:
 a second analgesic agent selected from the group consisting of acetaminophen, aspirin, ibuprofen, and naproxen,   wherein said second analgesic agent is different from said first analgesic agent and is administered orally at a daily dose of 5 mg to 2000 mg.   
     
     
         11 . The method of  claim 10 , wherein said second analgesic agent is administered orally at a daily dose of 50 mg to 500 mg. 
     
     
         12 . The method of  claim 11 , wherein said second analgesic agent is administered orally at a daily dose of 100 mg to 500 mg. 
     
     
         13 . The method of  claim 12 , wherein said second analgesic agent is administered orally at a daily dose of 250 mg to 500 mg. 
     
     
         14 . The method of  claim 10 , wherein said second analgesic agent is administered orally at a daily dose of 250 mg to 1000 mg. 
     
     
         15 . The method of  claim 1 , wherein said pharmaceutical composition further comprises one or more antimuscarinic agents selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine. 
     
     
         16 . The method of  claim 1 , wherein said pharmaceutical composition further comprises one or more antidiuretics. 
     
     
         17 . The method of  claim 1 , wherein said pharmaceutical composition further comprises one or more spasmolytics. 
     
     
         18 . The method of  claim 1 , further comprising:
 administering to said subject a diuretic;   wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said pharmaceutical composition is administered within 2 hours prior to said target time.   
     
     
         19 . A method for reducing the frequency of urination, comprising:
 administering orally to a subject in need thereof an effective amount of a pharmaceutical composition comprising a plurality of active ingredients,   wherein said plurality of active ingredients comprises: (1) one or more analgesic agents and (2) one or more antimuscarinic agents, and wherein said one or more analgesic agents are administered at a combined daily dose of 5 mg to 2000 mg.   
     
     
         20 . The method of  claim 19 , wherein said pharmaceutical composition is formulated for immediate-release of said plurality of active ingredients. 
     
     
         21 . The method of  claim 19 , wherein said pharmaceutical composition contains two active ingredients, one is formulated for immediate-release and the other one is formulated for delayed-release. 
     
     
         22 . The method of  claim 19 , wherein said pharmaceutical composition contains two active ingredients, both active ingredients are formulated for immediate-release and delayed-release. 
     
     
         23 . The method of  claim 19 , wherein said pharmaceutical composition contains two active ingredients, one is formulated for delayed-release at a first time point and the other one is formulated for delayed-release at a second time point. 
     
     
         24 . The method of  claim 19 , wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, and acetaminophen, and wherein said one or more antimuscarinic agents are selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine. 
     
     
         25 . The method of  claim 19 , wherein said plurality of active ingredients consist of two analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen, and acetaminophen. 
     
     
         26 . The method of  claim 19 , wherein said plurality of active ingredients further comprise one or more antidiuretics. 
     
     
         27 . The method of  claim 19 , wherein said plurality of active ingredients further comprise one or more spasmolytics. 
     
     
         28 . A pharmaceutical composition, comprising:
 one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen, and acetaminophen;   one or more antidiuretics; and   a pharmaceutically acceptable carrier,   wherein at least one of said one or more analgesic agents is formulated for delayed-release.   
     
     
         29 . The pharmaceutical composition of  claim 28 . 
     
     
         30 . The pharmaceutical composition of  claim 28 , further comprise one or more spasmolytics.